Plant Bioscience Ltd transfers control of Hypertrans® Plant-based Biologics and Vaccines Expression Technology to Leaf Expression Systems Ltd

14 May 2019

Norwich Research Park occupiers Plant Bioscience Ltd (PBL) and Leaf Expression Systems Ltd (Leaf) are delighted to announce a further development in their relationship, with PBL granting Leaf the exclusive rights to sub-license the Hypertrans® transient expression system, the core technology underpinning Leaf’s biologics and vaccines contract development and manufacturing services business. Apart from rights previously granted to PBL’s pre-existing licensees, this effectively transfers to Leaf full control of the Hypertrans® technology and associated patented intellectual property. This extension of Leaf’s rights will ensure that Leaf’s clients are able to use Hypertrans® for the manufacture of their products in multiple geographical locations to meet the needs of individual markets and to enable clients to take advantage of lower manufacturing costs in some of these markets.

Leaf’s CEO Simon Saxby commented “I am delighted that we have strengthened our relationship with PBL and that we can now offer our clients the assurances they need in order to plan for scale up manufacture using Hypertrans® in the locations that are most appropriate for the target indications of their new biologic drugs or vaccines”.

PBL’s Managing Director Dr Jan Chojecki added “Leaf has been outstandingly successful in establishing its technical operations and developing its customer base and partnering activity. Now is the time to put Leaf fully in the driving seat with regard to this important and proprietary intellectual property asset developed originally by Professor George Lomonossoff at the John Innes Centre”.